SuperGen Planning Dacogen NDA Submission For Myelodysplastic Syndrome In Third Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
The company plans to begin the fast-track decitabine NDA submission in the second quarter and complete submission in the third quarter. Pharmion’s MDS agent could come to market before then – Vidaza (azacitadine) has a user fee date of June 29.
You may also be interested in...
MGI Pharma Adding Three Compounds in Three Deals
Mergers with Aesgen and Zycos and a licensing deal with Supergen give MGI pipeline products that dovetail with the sales needs of its existing anti-emetic Aloxi.
Madrigal’s FDA Approval In MASH Ends Years Of Industry Frustration
As the first approved MASH (formerly NASH) therapy, nearly four years after initially anticipated, Madrigal gets the opportunity to establish a MASH marketplace with Rezdiffra (resmetirom).